The top gastroenterology biosimilar news from 2024 highlight fluctuations in the adalimumab biosimilar market throughout the ...
A recent study showed similar safety and efficacy of a bevacizumab biosimilar compared with the reference product (Avastin) ...
Number 3: Sandoz's biosimilar denosumab (Jubbonti/Wyost) has demonstrated analytical, pharmacokinetic, pharmacodynamic, and clinical equivalence to reference denosumab (Prolia/Xgeva), supporting its ...
A systematic review identified 13 strategies, including patient and provider education, empathetic communication, and shared ...
Health Canada has approved Omlyclo, the first omalizumab biosimilar in Canada, for the treatment of chronic idiopathic ...
China's trastuzumab biosimilar market is growing but lags behind European countries, with biosimilars gradually increasing ...
The FDA approved Celltrion's Steqeyma (ustekinumab-stba), making it the seventh biosimilar slated to compete against blockbuster Stelara (reference ustekinumab) in 2025. The FDA has approved Steqeyma ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback